Sequential or Simultaneous Injection of Preformed Fibrils and AAV Overexpression of Alpha-Synuclein Are Equipotent in Producing Relevant Pathology and Behavioral Deficits.

AAV Parkinson’s disease alpha synuclein behavioral deficits dopamine inflammation motor deficits phosphorylated synuclein preclinical rodent model preformed fibrils

Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2022
Historique:
pubmed: 26 2 2022
medline: 3 6 2022
entrez: 25 2 2022
Statut: ppublish

Résumé

Preclinical rodent models for Parkinson's disease (PD) based on viral human alpha-synuclein (h-αSyn) overexpression recapitulate some of the pathological hallmarks as it presents in humans, such as progressive cell loss and additional synucleinopathy in cortical and subcortical structures. Recent studies have combined viral vector-based overexpression of human wild-type αSyn with the sequential or simultaneous inoculation of preformed fibrils (PFFs) derived from human αSyn. The goal of the study was to investigate whether sequential or combined delivery of the AAV vector and the PFFs are equipotent in inducing stable neurodegeneration and behavioral deficits. Here we compare between four experimental paradigms (PFFs only, AAV-h-αSyn only, AAV-h-αSyn with simultaneous PFFs, and AAV-h-αSyn with sequential PFFs) and their respective GFP control groups. We observed reduction of TH expression and loss of neurons in the midbrain in all AAV (h-αSyn or GFP) injected groups, with or without additional PFFs inoculation. The overexpression of either h-αSyn or GFP alone induced motor deficits and dysfunctional dopamine release/reuptake in electrochemical recordings in the ipsilateral striatum. However, we observed a substantial formation of insoluble h-αSyn aggregates and inflammatory response only when h-αSyn and PFFs were combined. Moreover, the presence of h-αSyn induced higher axonal pathology compared to control groups. Simultaneous AAV and PFFs injections are equipotent in the presented experimental setup in inducing histopathological and behavioral changes. This model provides new and interesting possibilities for characterizing PD pathology in preclinical models and means to assess future therapeutic interventions.

Sections du résumé

BACKGROUND
Preclinical rodent models for Parkinson's disease (PD) based on viral human alpha-synuclein (h-αSyn) overexpression recapitulate some of the pathological hallmarks as it presents in humans, such as progressive cell loss and additional synucleinopathy in cortical and subcortical structures. Recent studies have combined viral vector-based overexpression of human wild-type αSyn with the sequential or simultaneous inoculation of preformed fibrils (PFFs) derived from human αSyn.
OBJECTIVE
The goal of the study was to investigate whether sequential or combined delivery of the AAV vector and the PFFs are equipotent in inducing stable neurodegeneration and behavioral deficits.
METHODS
Here we compare between four experimental paradigms (PFFs only, AAV-h-αSyn only, AAV-h-αSyn with simultaneous PFFs, and AAV-h-αSyn with sequential PFFs) and their respective GFP control groups.
RESULTS
We observed reduction of TH expression and loss of neurons in the midbrain in all AAV (h-αSyn or GFP) injected groups, with or without additional PFFs inoculation. The overexpression of either h-αSyn or GFP alone induced motor deficits and dysfunctional dopamine release/reuptake in electrochemical recordings in the ipsilateral striatum. However, we observed a substantial formation of insoluble h-αSyn aggregates and inflammatory response only when h-αSyn and PFFs were combined. Moreover, the presence of h-αSyn induced higher axonal pathology compared to control groups.
CONCLUSION
Simultaneous AAV and PFFs injections are equipotent in the presented experimental setup in inducing histopathological and behavioral changes. This model provides new and interesting possibilities for characterizing PD pathology in preclinical models and means to assess future therapeutic interventions.

Identifiants

pubmed: 35213388
pii: JPD212555
doi: 10.3233/JPD-212555
pmc: PMC9198765
doi:

Substances chimiques

alpha-Synuclein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1133-1153

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK108798
Pays : United States

Références

Int J Mol Sci. 2021 Jun 23;22(13):
pubmed: 34201785
Nature. 2015 Jun 18;522(7556):340-4
pubmed: 26061766
Methods Mol Biol. 2019;1937:101-124
pubmed: 30706392
Brain. 2019 Mar 1;142(3):512-525
pubmed: 30808022
Nat Rev Neurosci. 2021 Feb;22(2):111-131
pubmed: 33432241
Nat Cell Biol. 2002 Feb;4(2):160-4
pubmed: 11813001
Sci Rep. 2018 Jul 17;8(1):10788
pubmed: 30018327
PLoS One. 2010 Jan 20;5(1):e8784
pubmed: 20098715
J Neurol. 2000 Apr;247 Suppl 2:II3-10
pubmed: 10991663
PLoS One. 2013;8(1):e55375
pubmed: 23383169
Neuroscience. 2012 Feb 17;203:170-9
pubmed: 22198020
J Neurosci. 1995 May;15(5 Pt 2):3863-75
pubmed: 7751951
Mov Disord. 2019 Nov;34(11):1699-1710
pubmed: 31449702
Acta Neuropathol. 2012 May;123(5):653-69
pubmed: 22361813
Mol Neurodegener. 2020 Sep 8;15(1):49
pubmed: 32900375
Mol Neurodegener. 2013 Nov 25;8:44
pubmed: 24267638
J Neurosci Res. 2019 Mar;97(3):346-361
pubmed: 30548446
Science. 2012 Nov 16;338(6109):949-53
pubmed: 23161999
Cell Tissue Res. 1996 Nov;286(2):225-33
pubmed: 8854891
Neuropharmacology. 2000 Mar 3;39(5):777-87
pubmed: 10699444
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8
pubmed: 12122208
Brain. 2021 Dec 16;144(11):3477-3491
pubmed: 34297092
Neuroscience. 2015 Aug 27;302:47-58
pubmed: 25684748
Neurobiol Aging. 2015 Mar;36(3):1543-58
pubmed: 25599874
Brain Res Bull. 2008 Nov 25;77(5):312-9
pubmed: 18817852
EBioMedicine. 2020 Sep;59:102944
pubmed: 32810825
Hum Gene Ther. 2002 Mar 20;13(5):605-12
pubmed: 11916484
J Neurochem. 2004 Oct;91(2):451-61
pubmed: 15447678
Hum Mol Genet. 2009 Mar 1;18(5):872-87
pubmed: 19074459
PLoS One. 2013 Nov 27;8(11):e81426
pubmed: 24312298
Mol Ther Nucleic Acids. 2017 Sep 15;8:184-197
pubmed: 28918020
Transl Neurodegener. 2013 Feb 11;2(1):4
pubmed: 23398715
J Parkinsons Dis. 2020;10(4):1335-1342
pubmed: 32716322
Neurobiol Dis. 2013 Aug;56:145-55
pubmed: 23643841
Science. 1997 Feb 7;275(5301):838-41
pubmed: 9012352
Brain Res. 1970 Dec 18;24(3):485-93
pubmed: 5494536
Neurosci Lett. 1985 Dec 18;62(3):389-94
pubmed: 3912685
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8284-E8293
pubmed: 28900002
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
Hum Gene Ther Methods. 2014 Apr;25(2):115-25
pubmed: 24328707
Neuron. 2019 Aug 21;103(4):627-641.e7
pubmed: 31255487
Curr Chem Genomics. 2009 May 28;3:22-32
pubmed: 20161833
Sci Rep. 2020 Mar 17;10(1):4895
pubmed: 32184415
Neurobiol Dis. 2015 Oct;82:185-199
pubmed: 26093169
Exp Neurol. 2012 May;235(1):306-15
pubmed: 22394547
Neuron. 2016 Jun 1;90(5):955-68
pubmed: 27161524
J Neurochem. 2004 Jun;89(6):1318-24
pubmed: 15189334
Sci Rep. 2016 Apr 14;6:24526
pubmed: 27075649
J Parkinsons Dis. 2019;9(2):301-313
pubmed: 30829619
Mol Ther. 2006 Mar;13(3):517-27
pubmed: 16325474
J Neurochem. 1998 Jan;70(1):179-89
pubmed: 9422361
Brain Pathol. 2003 Jul;13(3):364-72
pubmed: 12946025
Ann Neurol. 2017 Jun;81(6):825-836
pubmed: 28470693
Exp Neurol. 1998 Aug;152(2):259-77
pubmed: 9710526
J Pharmacol Exp Ther. 1985 Oct;235(1):259-65
pubmed: 2864435
Brain. 1991 Oct;114 ( Pt 5):2283-301
pubmed: 1933245
J Parkinsons Dis. 2016;6(1):1-15
pubmed: 27003783
Nat Commun. 2013;4:2575
pubmed: 24108358
J Neurosci. 2002 Apr 1;22(7):2780-91
pubmed: 11923443
Behav Brain Res. 2013 Jan 15;237:215-22
pubmed: 23022749
J Neurosci Methods. 2011 Aug 30;200(1):29-35
pubmed: 21723319
Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17510-5
pubmed: 15576511
Neurobiol Dis. 2012 Mar;45(3):939-53
pubmed: 22182688
Brain. 2011 Aug;134(Pt 8):2302-11
pubmed: 21712347
Neurobiol Dis. 2013 Aug;56:47-58
pubmed: 23567651
Science. 2003 Apr 25;300(5619):636-40
pubmed: 12714745
Cell Rep. 2016 Sep 20;16(12):3373-3387
pubmed: 27653697
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):763-8
pubmed: 18178617
Brain Res. 1969 Jul;14(2):461-71
pubmed: 4893861
J Neuroimmune Pharmacol. 2013 Mar;8(1):94-117
pubmed: 23054368
Eur Neuropsychopharmacol. 2007 Feb;17(3):206-14
pubmed: 16750350
Mol Neurodegener. 2010 Oct 28;5:43
pubmed: 21029459
J Neurol Sci. 1997 Oct 3;151(1):83-7
pubmed: 9335015
Neurobiol Dis. 2017 Sep;105:84-98
pubmed: 28576704
J Biol Chem. 2003 Nov 7;278(45):44405-11
pubmed: 12923179
Proc Natl Acad Sci U S A. 2013 May 7;110(19):E1817-26
pubmed: 23610405
Neurosci Lett. 1994 Nov 21;182(1):107-11
pubmed: 7891873
Arch Neurol. 2006 Apr;63(4):584-8
pubmed: 16606773
J Parkinsons Dis. 2019;9(1):17-29
pubmed: 30741691
Prog Brain Res. 2010;184:89-111
pubmed: 20887871
J Neurosci. 2009 Mar 18;29(11):3365-73
pubmed: 19295143
PLoS One. 2011 Mar 07;6(3):e17698
pubmed: 21408191
PLoS One. 2014 Jul 07;9(7):e100869
pubmed: 24999658
Brain Res. 1987 Mar 3;405(1):26-38
pubmed: 2882814
Eur J Neurosci. 2017 Feb;45(4):536-547
pubmed: 27893183
Brain. 2013 Apr;136(Pt 4):1128-38
pubmed: 23466394
Exp Neurol. 2013 Sep;247:485-95
pubmed: 23360805
J Vis Exp. 2017 Sep 1;(127):
pubmed: 28892024
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15209-15220
pubmed: 32541058
J Biol Chem. 2002 Dec 13;277(50):49071-6
pubmed: 12377775
Neuron. 2011 Oct 6;72(1):57-71
pubmed: 21982369
Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3213-9
pubmed: 22315428
J Biol Chem. 2006 Oct 6;281(40):29739-52
pubmed: 16847063

Auteurs

Matilde Negrini (M)

Behavioural Neuroscience Laboratory, Department of Experimental Medical Sciences, Lund University, Lund, Sweden.

Giuseppe Tomasello (G)

Behavioural Neuroscience Laboratory, Department of Experimental Medical Sciences, Lund University, Lund, Sweden.

Marcus Davidsson (M)

Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ, USA.
Molecular Neuromodulation, Department of Experimental Medical Sciences, Lund University, Lund, Sweden.

Alexis Fenyi (A)

Institut Francois Jacob (MIRCen), CEA and Laboratory of Neurodegenerative Diseases, CNRS, Fontenay-aux-Roses, France.

Cécile Adant (C)

Behavioural Neuroscience Laboratory, Department of Experimental Medical Sciences, Lund University, Lund, Sweden.

Swantje Hauser (S)

Behavioural Neuroscience Laboratory, Department of Experimental Medical Sciences, Lund University, Lund, Sweden.

Elena Espa (E)

Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Sciences, Lund University, Lund, Sweden.

Francesco Gubinelli (F)

Behavioural Neuroscience Laboratory, Department of Experimental Medical Sciences, Lund University, Lund, Sweden.

Fredric P Manfredsson (FP)

Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ, USA.

Ronald Melki (R)

Institut Francois Jacob (MIRCen), CEA and Laboratory of Neurodegenerative Diseases, CNRS, Fontenay-aux-Roses, France.

Andreas Heuer (A)

Behavioural Neuroscience Laboratory, Department of Experimental Medical Sciences, Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH